Performance in the Real World Central to New Drug's Success

Time was that getting a new medicine over the goal line equated to receiving the "green light" for approval from the FDA. In today's environment of government austerity measures and shrinking health care budgets, however, a drug's approval now only represents a "first and goal." To achieve a "touchdown" drug developers are going to have to demonstrate favorable pharmacoeconomics and real-world value for their products.